A team of investigators at City of Hope funded by the Prostate Cancer Foundation reports that patients with advanced prostate cancer can be safely treated with chimeric antigen receptor T cell therapy.
LOS ANGELES, June 12, 2024 /PRNewswire/ -- A team of investigators at City of Hope funded by the Prostate Cancer Foundation (PCF) reports that patients with advanced prostate cancer can be safely treated with chimeric antigen receptor (CAR) T cell therapy. The results of their first-in-human phase 1 clinical trial, which also showed promising therapeutic activity, were published today in Nature Medicine.
“This represents an important advance against metastatic castration-resistant prostate cancer (mCRPC) which continues to claim more than 30,000 men’s lives each year,” said Howard R. Soule, PhD, Executive Vice President, Chief Science Officer and Lori and Michael Milken Chair of the Prostate Cancer Foundation. “PCF is proud to invest in this crucial work which advances our mission to end death and suffering from prostate cancer, and we look forward to seeing their future progress with PSCA-directed CAR T cell therapy.”
Saul Priceman, PhD, City of Hope associate professor, Department of Hematology & Hematopoietic Cell Transplantation, and team developed CAR T cells that target prostate stem cell antigen (PSCA), which is highly expressed in prostate cancer. The phase 1 trial treated 14 PSCA-positive patients with mCRPC, which had spread beyond the prostate and no longer responded to hormone treatment, using the PSCA-directed CAR T-cell therapy. Patients’ own immune system T cells were reprogrammed in a laboratory with a CAR to recognize and attack the PSCA protein on the surface of cancer cells. The CAR T cells were then infused back into the patients who were monitored for a 28-day study period.
“Our trial’s major finding is that PSCA-directed CAR T cells are safe and do work against mCRPC,” said Priceman. “This opens up the opportunity to continue to develop this type of cellular immunotherapy for these patients, who currently have no other effective treatment options.”
The goal of the phase 1 study was to examine the therapy’s safety and dose-limiting toxicities and gather preliminary data on efficacy of the approach.
To assess the safety of CAR T cells alone, patients received a single infusion of 100 million CAR T cells without having prior lymphodepletion chemotherapy, which is routinely used in blood cancers to improve the efficacy of CAR T cell treatment. This was followed by incorporation of lymphodepletion at the same CAR T cell dose. Researchers found that with lymphodepletion, there was a side effect of cystitis, or irritation of the bladder. Since PSCA is also found in the bladder, it is likely the CAR T cells attacked the bladder cells, causing inflammation, they concluded. Historically, cyclophosphamide, which is part of the lymphodepletion regimen, can also cause cystitis. When the team reduced the dose of cyclophosphamide, the toxicity was largely mitigated in patients.
Four of the 14 patients had declines in their PSA levels, which is a biomarker of disease progression in prostate cancer, including one patient with significant decline. Furthermore, imaging showed therapeutic responses in some of the treated patients.
One patient’s PSA level decreased by 95% and the cancer that had spread to his bones and soft tissue also declined. He experienced this positive response for approximately eight months.
Five of the 14 patients had mild or moderate cytokine release syndrome, a systemic inflammatory response characterized by fever, nausea, fatigue, and other symptoms, and considered a common and treatable side effect of CAR T cell therapy.
One limiting factor of the therapy’s effectiveness is that CAR T cells did not persist in patients at high levels beyond the 28-day monitoring period. This is a common challenge in solid tumor CAR T cell therapy that the researchers will address in a phase 1B trial using the PSCA-CAR T cell therapy in a repeat dosing strategy and in combination with radiation to enhance anti-tumor activity. The City of Hope trial is currently enrolling patients.
This body of work was leveraged into a 2022 PCF TACTICAL (Therapy ACceleration To Intercept Cancer Lethality) Award which supports large-scale, pioneering, multi-institutional team research projects addressing metastatic, lethal prostate cancer. The team with principal and co-investigators from the University of Pennsylvania, City of Hope, Children’s Hospital of Philadelphia, the National Cancer Institute, the National Institute on Aging, the University of Southern California, and The Corporal Michael J. Crescenz VA Medical Center were awarded $10 million over three years to fund their project Developing Engineered Cell Therapies for Metastatic Castrate-Resistant Prostate Cancer to Increase Efficacy and Decrease Toxicity.
About the Prostate Cancer Foundation
The Prostate Cancer Foundation (PCF) is the world’s leading philanthropic organization dedicated to funding life-saving prostate cancer research. Founded in 1993 by Mike Milken, PCF has been responsible for raising more than $1 billion in support of cutting-edge research through more than 2,250 research projects at 245 leading cancer centers, with a global footprint spanning 28 countries. Since PCF’s inception, and through its efforts, patients around the world are living longer, suffering fewer complications, and enjoying better quality of all life. PCF is committed to creating a global public square for prostate cancer, in service to our mission of ending death and suffering from the disease. Learn more at pcf.org.
MEDIA CONTACT:
Staci L. Vernick
Prostate Cancer Foundation
svernick@pcf.org/press@pcf.org
610-812-6092
View original content to download multimedia:https://www.prnewswire.com/news-releases/prostate-cancer-foundation-funded-research-shows-promising-results-against-lethal-form-of-prostate-cancer-302170198.html
SOURCE Prostate Cancer Foundation
